Study data illustrate the potential benefits of controlling serum phosphate, intact parathyroid hormone, and calcium levels in patients with nondialysis-dependent chronic kidney disease.
In a large US study, only half of patients with stage 3, 4, and 5 had undergone PTH retesting at 12, 8, and 4.5 months, respectively, after treatment with vitamin D sterols, in line with KDIGO guidelines.
Elevated levels of 3 immune system biomarkers are associated with an increased risks for kidney failure requiring renal replacement therapy and death, a study found.
Sparsentan is an investigational small molecule candidate designed to selectively block the receptors of endothelin type A and angiotensin II type I, which are associated with kidney disease progression.
In a trial of patients with primary membranous nephropathy, corticosteroid-cyclophosphamide induced significantly more and faster remission of nephrotic syndrome than tacrolimus-rituximab.
For patients with sickle cell disease, HSCT may not be associated with a significant increase in CKD incidence or prevalence following transplantation.
Removing the race coefficient from the CKD-EPI equation could avert a potential systematic delay in kidney transplant eligibility of a median 1.9 years for Black patients, according to investigators.
A Swedish study of patients with moderate to severe chronic kidney disease found that women were less likely than men to experience disease progression and to die from any cause or cardiovascular causes.
